Marshall Wace
NGNE icon

Marshall Wace’s Neurogene NGNE Stock Holding History

Marshall Wace’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17,552
Closed -$206K – 3008
2025
Q1 		$206K Buy
+17,552
New +$305K ﹤0.01% 2396
2024
Q4 		– Sell
-9,980
Closed -$419K – 2864
2024
Q3 		$419K Sell
9,980
-31,467
-76% -$1.22M ﹤0.01% 1982
2024
Q2 		$1.51M Buy
41,447
+11,229
+37% +$396K ﹤0.01% 1499
2024
Q1 		$1.54M Buy
+30,218
New +$1.01M ﹤0.01% 1477
2021
Q4 		– Sell
-971
Closed -$140K – 4157
2021
Q3 		$140K Buy
+971
New +$149K ﹤0.01% 2851
2020
Q4 		– Sell
-6,198
Closed -$1.49M – 2081
2020
Q3 		$1.49M Buy
+6,198
New +$1.5M 0.01% 891
2018
Q4 		– Sell
-1,628
Closed -$95K – 1732
2018
Q3 		$95K Buy
+1,628
New +$96K ﹤0.01% 1100
2016
Q1 		– Sell
-2,027
Closed -$506K – 1141
2015
Q4 		$506K Buy
+2,027
New +$533K ﹤0.01% 803

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Marshall Wace's NGNE Position: Q2 2025 in Review

Marshall Wace sold out of Neurogene (NGNE) in Q2 2025, closing a stake of 17,552 shares — an estimated $206K sold.

Marshall Wace first reported a position in NGNE in Q4 2015 and held it in 8 quarters. The position peaked at $1.54M in Q1 2024. 82 funds tracked by Wall St. Rank hold NGNE as of Q2 2025.

  • Marshall Wace reported no remaining Neurogene position as of Q2 2025 after selling out during the quarter.
  • Marshall Wace sold 17,552 Neurogene shares in Q2 2025, an estimated $206K.
  • Marshall Wace first reported a position in Neurogene in Q4 2015 and held it in 8 quarters.
  • Marshall Wace's Neurogene position peaked at $1.54M in Q1 2024.
  • 82 funds tracked by Wall St. Rank held Neurogene as of Q2 2025.

Based on Marshall Wace's 13F filing for Q2 2025, filed 13 Aug 2025.